Clinical Trials

30 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04080284 2025-08-19

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

22 enrolled

Uterine Neoplasms, Endometrial Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

105 enrolled 29 charts

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

77 enrolled 8 charts

Ovarian Neoplasms

NCT03783949 2025-06-11

EUDARIO

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05990192 2025-04-22

SOPRANO

42 enrolled

Ovarian Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

7 enrolled

Classical hematologyGynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT03891576 2025-01-17

Newton

Phase 2 Terminated

83 enrolled

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

NCT04507841 2024-12-17

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2 Active not recruiting

67 enrolled

Ovarian Neoplasms

NCT03759600 2024-07-16

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

20 enrolled 42 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03759587 2024-06-07

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

19 enrolled 39 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03016338 2024-01-30

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

51 enrolled

Endometrial Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04716686 2024-01-05

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

83 enrolled

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT04284852 2023-12-15

NEOPRIMA

20 enrolled

Neoplasms, Ovarian Neoplasms

NCT05961124 2023-11-22

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

40 enrolled

Ovarian Neoplasms

NCT06141265 2023-11-21

BRAND

116 enrolled

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

NCT05751629 2023-04-21

COHORT-A

41 enrolled 17 charts

Ovarian Neoplasms

NCT05130515 2023-01-31

CC-ANNIE

6 enrolled

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

NCT05641506 2022-12-07

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

50 enrolled

Nausea, Ovarian Neoplasms

NCT02354586 2022-09-15

QUADRA

463 enrolled 15 charts 2 FDA

Ovarian Neoplasms

NCT03955471 2022-09-10

MOONSTONE

Phase 2 Terminated

41 enrolled 22 charts

Ovarian Neoplasms

NCT04392102 2022-08-29

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

15 enrolled

Ovarian Neoplasms

NCT05385068 2022-05-23

t

35 enrolled

Carcinoma, Ovarian Epithelial

NCT05311579 2022-04-13

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

36 enrolled

Ovarian Neoplasms

NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

167 enrolled

Fallopian Tube Neoplasms

NCT04217798 2021-09-01

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

36 enrolled

Ovarian Neoplasms

NCT04885413 2021-08-23

An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients

37 enrolled

Recurrent/ Advanced Stage Endometrial Cancer Patients

NCT04376073 2020-11-25

ANNIE

40 enrolled